세계의 편두통 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료제별, 투여 경로별, 유통 경로별, 지역별, 경쟁별(2020-2030년)
Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1728083
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 편두통 치료제 시장 규모는 2024년에 38억 9,000만 달러로 평가되었고, 2030년에는 50억 1,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 4.31%로 나타낼 전망입니다.
이 시장은 편두통 발생률 증가, 환자 인식 향상, 약물 개발의 빠른 진전 등으로 인해 안정적으로 확장되고 있습니다. 편두통은 만성 신경계 질환으로 전 세계적으로 많은 인구를 영향을 미치며 효과적인 치료 옵션에 대한 강한 수요를 창출하고 있습니다. 칼시토닌 유전자 관련 펩타이드(CGRP) 억제제 등과 같은 지속적인 혁신을 바탕으로 더 타겟팅되고 맞춤형 치료법으로의 전환이 진행 중입니다. 편두통의 공중 보건 및 경제적 영향에 대한 인식이 높아지면서 공공 및 민간 부문 모두에서 연구 개발(R&D) 투자가 증가하고 있습니다. 제약 기업들이 차세대 약물과 생물학적 제제의 출시를 집중적으로 추진함에 따라 시장은 더 효과적이고 맞춤형 치료 전략으로 계속 진화하고 있습니다. 이러한 혁신과 함께 건강 관리에 대한 인식 향상 및 접근성 개선은 지속 가능한 시장 성장을 지원할 것으로 예상됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모(2024년)
38억 9,000만 달러
시장 규모(2030년)
50억 1,000만 달러
CAGR(2025-2030년)
4.31%
급성장 부문
진통제
최대 시장
북미
시장 성장 촉진요인
편두통의 높은 유병률
주요 시장 과제
의약품 개발의 복잡성
주요 시장 동향
정밀 의학
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 임상시험 분석
제5장 고객의 목소리
제6장 세계의 편두통 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
치료제별 (통증 완화제(진통제, 트립탄, 에르고 알칼로이드 등), 예방제(혈압 강하제, 항경련제, 칼시토닌 유전자 관련 펩타이드(CGRP) 억제제, 기타 예방치료))
투여 경로별(경구 및 비강, 주사제)
유통 경로별(소매 약국, 병원 약국, 기타)
지역별
기업별(2024년)
시장 맵
제7장 북미의 편두통 치료제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제8장 유럽의 편두통 치료제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제9장 아시아태평양의 편두통 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제10장 남미의 편두통 치료제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제11장 중동 및 아프리카의 편두통 치료제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제12장 시장 역학
성장 촉진요인
과제
제13장 시장 동향과 발전
최근 동향
합병과 인수
제14장 세계의 편두통 치료제 시장 : SWOT 분석
제15장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체 치료법의 위협
제16장 경쟁 구도
Amgen Inc.
Teva Pharmaceutical Industries Limited
GlaxoSmithKline plc
Eli Lilly and Company
Bausch Health Companies Inc.
Novartis AG
AbbVie Inc.
Lundbeck Inc
Dr. Reddy및#39;s Laboratories Limited
Impel Pharmaceuticals Inc
제17장 전략적 제안
제18장 기업 소개와 면책사항
HBR
영문 목차
영문목차
The Global Migraine Therapeutics Market was valued at USD 3.89 Billion in 2024 and is projected to reach USD 5.01 Billion by 2030, growing at a CAGR of 4.31% during the forecast period. This market is expanding steadily due to the rising incidence of migraine, growing patient awareness, and rapid advancements in drug development. Migraine, a chronic neurological condition, affects a significant global population, leading to strong demand for effective treatment options. A notable shift is occurring toward more targeted and individualized therapies, supported by ongoing innovations such as calcitonin gene-related peptide (CGRP) inhibitors and gepants, which are demonstrating promising clinical outcomes. Increased recognition of migraine's public health and economic impacts has also driven investment in R&D by both public and private sectors. With pharmaceutical companies focusing on introducing next-generation drugs and biologics, the market continues to evolve toward more effective and personalized treatment strategies. These innovations, along with greater awareness and improved access to healthcare, are expected to support sustained market growth.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 3.89 Billion
Market Size 2030
USD 5.01 Billion
CAGR 2025-2030
4.31%
Fastest Growing Segment
Pain-Relieving Medications
Largest Market
North America
Key Market Drivers
High Prevalence of Migraine
The widespread occurrence of migraine is a key driver fueling the growth of the Migraine Therapeutics Market. Migraine affects individuals of all ages, genders, and demographics, making it a pervasive public health issue. The condition is a leading cause of disability and contributes to significant losses in productivity, impacting both individuals and economies. As per a March 2024 WHO report, around 40% of the global population-approximately 3.1 billion people-suffered from migraines and other headache disorders as of 2021. The condition shows a higher prevalence among women, likely due to hormonal factors. Migraine ranks among the top three neurological disorders from childhood through late adulthood. This widespread burden has led to increased attention from healthcare stakeholders, driving awareness, diagnosis, and treatment. The rising recognition of migraine's impact on quality of life has also encouraged the development and uptake of more effective therapies, including CGRP inhibitors and gepants, further expanding the market.
Key Market Challenges
Drug Development Complexity
Developing effective migraine therapeutics presents significant challenges due to the complex nature of the condition. Migraine manifests with diverse symptoms and triggers, requiring a deep understanding of its neurological basis for effective drug design. Identifying precise molecular targets is difficult, as the underlying mechanisms of migraine are still not fully understood. The clinical trial process for migraine treatments can be lengthy and costly, involving large patient populations and extended follow-up periods. Subjective symptom reporting and placebo responses add further complexity. Regulatory agencies such as the FDA require comprehensive evidence of safety and efficacy, necessitating rigorous testing and data collection. In addition, evolving clinical trial endpoints demand constant adaptation from researchers and sponsors. These challenges, combined with high development costs, can delay innovation and restrict market entry, particularly for smaller firms.
Key Market Trends
Precision Medicine
Precision medicine is emerging as a transformative trend in the Migraine Therapeutics Market, offering more effective and individualized treatment strategies. By utilizing genetic, molecular, and clinical data, precision medicine allows for the customization of therapies based on a patient's unique migraine profile. Advances in genetic testing and biomarker analysis enable pharmaceutical developers and healthcare providers to better identify subgroups of patients who are most likely to benefit from specific treatments. This targeted approach improves treatment outcomes, reduces side effects, and enhances patient satisfaction. For pharmaceutical companies, precision medicine increases the efficiency of drug development and can lead to faster regulatory approvals. It also offers the potential for higher market differentiation and pricing power. As demand grows for more personalized healthcare solutions, the integration of precision medicine into migraine treatment protocols is expected to expand significantly, reshaping the market landscape and improving therapeutic success rates.
Key Market Players
Amgen Inc.
Teva Pharmaceutical Industries Limited
GlaxoSmithKline plc
Eli Lilly and Company
Bausch Health Companies Inc.
Novartis AG
AbbVie Inc.
Lundbeck Inc
Dr. Reddy's Laboratories Limited
Impel Pharmaceuticals Inc
Report Scope:
In this report, the Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Migraine Therapeutics Market, Route of Administration:
Oral & Nasal
Injectables
Migraine Therapeutics Market, Distribution Channel:
Retail Pharmacy
Hospital Pharmacy
Others
Migraine Therapeutics Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Migraine Therapeutics Market.
Available Customizations:
Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Clinical Trial Analysis
4.1. Ongoing Clinical Trials
4.2. Completed Clinical Trials
4.3. Terminated Clinical Trials
4.4. Breakdown of Pipeline, By Development Phase
4.5. Breakdown of Pipeline, By Status
4.6. Breakdown of Pipeline, By Therapeutic Area
4.7. Breakdown of Pipeline. By Region
4.8. Clinical Trials Heat Map
5. Voice of Customer
6. Global Migraine Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
6.2.2. By Route of Administration (Oral & Nasal, Injectables)
6.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
7. North America Migraine Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutics
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Migraine Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutics
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Canada Migraine Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutics
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. Mexico Migraine Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutics
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
8. Europe Migraine Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutics
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Migraine Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutics
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. United Kingdom Migraine Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutics
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Italy Migraine Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutics
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. France Migraine Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutics
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Spain Migraine Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutics
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Asia-Pacific Migraine Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutics
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Migraine Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutics
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. India Migraine Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutics
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. Japan Migraine Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutics
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
9.3.4. South Korea Migraine Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapeutics
9.3.4.2.2. By Route of Administration
9.3.4.2.3. By Distribution Channel
9.3.5. Australia Migraine Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapeutics
9.3.5.2.2. By Route of Administration
9.3.5.2.3. By Distribution Channel
10. South America Migraine Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutics
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Migraine Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutics
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Argentina Migraine Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutics
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Colombia Migraine Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutics
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Middle East and Africa Migraine Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapeutics
11.2.2. By Route of Administration
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Migraine Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapeutics
11.3.1.2.2. By Route of Administration
11.3.1.2.3. By Distribution Channel
11.3.2. Saudi Arabia Migraine Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapeutics
11.3.2.2.2. By Route of Administration
11.3.2.2.3. By Distribution Channel
11.3.3. UAE Migraine Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapeutics
11.3.3.2.2. By Route of Administration
11.3.3.2.3. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Development
13.2. Mergers & Acquisitions
14. Global Migraine Therapeutics Market: SWOT Analysis
